Galapagos/€GLPG
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€GLPG
Sector
Primary listing
AEX
Employees
558
Headquarters
Website
Galapagos Metrics
BasicAdvanced
€1.8B
-
-€6.62
-
-
Price and volume
Market cap
€1.8B
52-week high
€32.64
52-week low
€20.00
Average daily volume
3.5K
Financial strength
Current ratio
8.626
Quick ratio
8.533
Long term debt to equity
0.236
Total debt to equity
0.307
Interest coverage (TTM)
-149.99%
Profitability
EBITDA (TTM)
-277.266
Gross margin (TTM)
84.31%
Net profit margin (TTM)
-151.94%
Operating margin (TTM)
-111.14%
Effective tax rate (TTM)
4.18%
Revenue per employee (TTM)
€510,000
Management effectiveness
Return on assets (TTM)
-5.19%
Return on equity (TTM)
-16.72%
Valuation
Price to revenue (TTM)
6.184
Price to book
0.72
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-6.175
Free cash flow yield (TTM)
-16.19%
Free cash flow per share (TTM)
-4.361
Growth
Revenue change (TTM)
10.31%
Earnings per share change (TTM)
-311.04%
3-year revenue growth (CAGR)
-20.78%
10-year revenue growth (CAGR)
14.43%
3-year earnings per share growth (CAGR)
327.42%
10-year earnings per share growth (CAGR)
11.88%
What the Analysts think about Galapagos
Analyst ratings (Buy, Hold, Sell) for Galapagos stock.
Bulls say / Bears say
Galapagos’ cell therapy business attracted multiple non-binding offers from financial investors, showing strong external interest and the possibility to unlock considerable value from a divestment. (Reuters)
Galapagos entered into an oncology partnership with Servier, securing €2 million in research access fees and up to €260 million in milestone payments, providing non-dilutive funding for its immuno-oncology pipeline. (Fierce Biotech)
The GLPG5101 CD19 CAR-T program was extended to include eight aggressive B-cell cancers, considerably expanding its high-value oncology portfolio. (BeyondSPX)
Galapagos reported a net loss of €153.4 million for Q1 2025, compared to a €90.2 million profit in the same quarter last year, highlighting ongoing operational losses. (Galapagos Q1 2025 Results)
The planned spin-off of its innovative medicines unit was reassessed in May 2025, due to negative regulatory and market factors, leading to uncertainty over timing and value realization. (Reuters)
Galapagos expects an annual cash burn of €175–225 million, which could reduce its projected €500 million post-spin-off cash by 2028, potentially requiring new fundraising in a tough market. (Galapagos Q1 2025 Results)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Galapagos Financial Performance
Revenues and expenses
Galapagos Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of €1.8B as of November 07, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of November 07, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) does not currently have a Beta indicator.